Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults

Jeffrey M. Jacobson, Jacob P. Lalezari, Melanie A. Thompson, Carl J. Fichtenbaum, Michael S. Saag, Barry S. Zingman, Paul D'Ambrosio, Nancy Stambler, Yakov Rotshteyn, Andre J. Marozsan, Paul J. Maddon, Stephen A. Morris, William C. Olson

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The anti-CCR5 antibody PRO 140 has shown potent and prolonged antiretroviral activity in subjects infected with CCR5-tropic (R5) HIV-1. Prior studies have examined single intravenous doses ranging up to 5 mg/kg of body weight or up to three subcutaneous doses ranging up to 324 mg. Here we report the results of a randomized, double-blind, placebo-controlled trial that examined the antiviral activity, tolerability, and pharmacokinetics of single 5-mg/kg and 10-mg/kg intravenous infusions of PRO 140 in 31 treated subjects. Eligibility criteria included HIV-1 RNA levels of >5,000 copies/ml, CD4 + cell counts of >300/μl, no antiretroviral therapy for >12 weeks, and detection of only R5 HIV-1 in the original Trofile assay. Following poststudy testing with an enhanced-sensitivity Trofile assay, one subject treated with 10 mg/kg was reclassified as having dual/mixed-tropic virus at screening, and the data for that subject were censored from efficacy analyses. The mean maximum reduction of the HIV-1 RNA level from the baseline level was 1.8 log10 units for both the 5-mg/kg and 10-mg/kg doses (P < 0.0001 relative to placebo). Viral loads reached their nadir at day 12 posttreatment and remained significantly (P < 0.01) reduced through day 29 for both PRO 140 dose groups. Treatment was generally well tolerated, with no dose-limiting toxicity being observed. Peak serum concentrations and overall exposures increased proportionally with dose. In summary, single 5-mg/kg and 10-mg/kg doses of PRO 140 exhibited potent, long-lived antiviral activity and were generally well tolerated. The findings further delineate the safety and antiviral properties of this novel, long-acting antiretroviral agent.

Original languageEnglish (US)
Pages (from-to)4137-4142
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume54
Issue number10
DOIs
StatePublished - Oct 2010

Fingerprint

HIV-1
HIV
Antiviral Agents
Placebos
RNA
Anti-Retroviral Agents
CD4 Lymphocyte Count
Viral Load
Intravenous Infusions
Anti-Idiotypic Antibodies
Pharmacokinetics
Body Weight
Viruses
Safety
PRO-140 monoclonal antibody
Therapeutics
Serum

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Jacobson, J. M., Lalezari, J. P., Thompson, M. A., Fichtenbaum, C. J., Saag, M. S., Zingman, B. S., ... Olson, W. C. (2010). Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrobial Agents and Chemotherapy, 54(10), 4137-4142. https://doi.org/10.1128/AAC.00086-10

Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. / Jacobson, Jeffrey M.; Lalezari, Jacob P.; Thompson, Melanie A.; Fichtenbaum, Carl J.; Saag, Michael S.; Zingman, Barry S.; D'Ambrosio, Paul; Stambler, Nancy; Rotshteyn, Yakov; Marozsan, Andre J.; Maddon, Paul J.; Morris, Stephen A.; Olson, William C.

In: Antimicrobial Agents and Chemotherapy, Vol. 54, No. 10, 10.2010, p. 4137-4142.

Research output: Contribution to journalArticle

Jacobson, JM, Lalezari, JP, Thompson, MA, Fichtenbaum, CJ, Saag, MS, Zingman, BS, D'Ambrosio, P, Stambler, N, Rotshteyn, Y, Marozsan, AJ, Maddon, PJ, Morris, SA & Olson, WC 2010, 'Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults', Antimicrobial Agents and Chemotherapy, vol. 54, no. 10, pp. 4137-4142. https://doi.org/10.1128/AAC.00086-10
Jacobson, Jeffrey M. ; Lalezari, Jacob P. ; Thompson, Melanie A. ; Fichtenbaum, Carl J. ; Saag, Michael S. ; Zingman, Barry S. ; D'Ambrosio, Paul ; Stambler, Nancy ; Rotshteyn, Yakov ; Marozsan, Andre J. ; Maddon, Paul J. ; Morris, Stephen A. ; Olson, William C. / Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. In: Antimicrobial Agents and Chemotherapy. 2010 ; Vol. 54, No. 10. pp. 4137-4142.
@article{cae002a143ba48c5be589257a0c5c774,
title = "Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults",
abstract = "The anti-CCR5 antibody PRO 140 has shown potent and prolonged antiretroviral activity in subjects infected with CCR5-tropic (R5) HIV-1. Prior studies have examined single intravenous doses ranging up to 5 mg/kg of body weight or up to three subcutaneous doses ranging up to 324 mg. Here we report the results of a randomized, double-blind, placebo-controlled trial that examined the antiviral activity, tolerability, and pharmacokinetics of single 5-mg/kg and 10-mg/kg intravenous infusions of PRO 140 in 31 treated subjects. Eligibility criteria included HIV-1 RNA levels of >5,000 copies/ml, CD4 + cell counts of >300/μl, no antiretroviral therapy for >12 weeks, and detection of only R5 HIV-1 in the original Trofile assay. Following poststudy testing with an enhanced-sensitivity Trofile assay, one subject treated with 10 mg/kg was reclassified as having dual/mixed-tropic virus at screening, and the data for that subject were censored from efficacy analyses. The mean maximum reduction of the HIV-1 RNA level from the baseline level was 1.8 log10 units for both the 5-mg/kg and 10-mg/kg doses (P < 0.0001 relative to placebo). Viral loads reached their nadir at day 12 posttreatment and remained significantly (P < 0.01) reduced through day 29 for both PRO 140 dose groups. Treatment was generally well tolerated, with no dose-limiting toxicity being observed. Peak serum concentrations and overall exposures increased proportionally with dose. In summary, single 5-mg/kg and 10-mg/kg doses of PRO 140 exhibited potent, long-lived antiviral activity and were generally well tolerated. The findings further delineate the safety and antiviral properties of this novel, long-acting antiretroviral agent.",
author = "Jacobson, {Jeffrey M.} and Lalezari, {Jacob P.} and Thompson, {Melanie A.} and Fichtenbaum, {Carl J.} and Saag, {Michael S.} and Zingman, {Barry S.} and Paul D'Ambrosio and Nancy Stambler and Yakov Rotshteyn and Marozsan, {Andre J.} and Maddon, {Paul J.} and Morris, {Stephen A.} and Olson, {William C.}",
year = "2010",
month = "10",
doi = "10.1128/AAC.00086-10",
language = "English (US)",
volume = "54",
pages = "4137--4142",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults

AU - Jacobson, Jeffrey M.

AU - Lalezari, Jacob P.

AU - Thompson, Melanie A.

AU - Fichtenbaum, Carl J.

AU - Saag, Michael S.

AU - Zingman, Barry S.

AU - D'Ambrosio, Paul

AU - Stambler, Nancy

AU - Rotshteyn, Yakov

AU - Marozsan, Andre J.

AU - Maddon, Paul J.

AU - Morris, Stephen A.

AU - Olson, William C.

PY - 2010/10

Y1 - 2010/10

N2 - The anti-CCR5 antibody PRO 140 has shown potent and prolonged antiretroviral activity in subjects infected with CCR5-tropic (R5) HIV-1. Prior studies have examined single intravenous doses ranging up to 5 mg/kg of body weight or up to three subcutaneous doses ranging up to 324 mg. Here we report the results of a randomized, double-blind, placebo-controlled trial that examined the antiviral activity, tolerability, and pharmacokinetics of single 5-mg/kg and 10-mg/kg intravenous infusions of PRO 140 in 31 treated subjects. Eligibility criteria included HIV-1 RNA levels of >5,000 copies/ml, CD4 + cell counts of >300/μl, no antiretroviral therapy for >12 weeks, and detection of only R5 HIV-1 in the original Trofile assay. Following poststudy testing with an enhanced-sensitivity Trofile assay, one subject treated with 10 mg/kg was reclassified as having dual/mixed-tropic virus at screening, and the data for that subject were censored from efficacy analyses. The mean maximum reduction of the HIV-1 RNA level from the baseline level was 1.8 log10 units for both the 5-mg/kg and 10-mg/kg doses (P < 0.0001 relative to placebo). Viral loads reached their nadir at day 12 posttreatment and remained significantly (P < 0.01) reduced through day 29 for both PRO 140 dose groups. Treatment was generally well tolerated, with no dose-limiting toxicity being observed. Peak serum concentrations and overall exposures increased proportionally with dose. In summary, single 5-mg/kg and 10-mg/kg doses of PRO 140 exhibited potent, long-lived antiviral activity and were generally well tolerated. The findings further delineate the safety and antiviral properties of this novel, long-acting antiretroviral agent.

AB - The anti-CCR5 antibody PRO 140 has shown potent and prolonged antiretroviral activity in subjects infected with CCR5-tropic (R5) HIV-1. Prior studies have examined single intravenous doses ranging up to 5 mg/kg of body weight or up to three subcutaneous doses ranging up to 324 mg. Here we report the results of a randomized, double-blind, placebo-controlled trial that examined the antiviral activity, tolerability, and pharmacokinetics of single 5-mg/kg and 10-mg/kg intravenous infusions of PRO 140 in 31 treated subjects. Eligibility criteria included HIV-1 RNA levels of >5,000 copies/ml, CD4 + cell counts of >300/μl, no antiretroviral therapy for >12 weeks, and detection of only R5 HIV-1 in the original Trofile assay. Following poststudy testing with an enhanced-sensitivity Trofile assay, one subject treated with 10 mg/kg was reclassified as having dual/mixed-tropic virus at screening, and the data for that subject were censored from efficacy analyses. The mean maximum reduction of the HIV-1 RNA level from the baseline level was 1.8 log10 units for both the 5-mg/kg and 10-mg/kg doses (P < 0.0001 relative to placebo). Viral loads reached their nadir at day 12 posttreatment and remained significantly (P < 0.01) reduced through day 29 for both PRO 140 dose groups. Treatment was generally well tolerated, with no dose-limiting toxicity being observed. Peak serum concentrations and overall exposures increased proportionally with dose. In summary, single 5-mg/kg and 10-mg/kg doses of PRO 140 exhibited potent, long-lived antiviral activity and were generally well tolerated. The findings further delineate the safety and antiviral properties of this novel, long-acting antiretroviral agent.

UR - http://www.scopus.com/inward/record.url?scp=77957349209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957349209&partnerID=8YFLogxK

U2 - 10.1128/AAC.00086-10

DO - 10.1128/AAC.00086-10

M3 - Article

VL - 54

SP - 4137

EP - 4142

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 10

ER -